Estimates of the 3-year rates or incidences by treatment group
End point . | Group A, G-CSF-/- . | Group B, G-CSF+/- . | Group C, G-CSF-/+ . | Group D, G-CSF+/+ . |
|---|---|---|---|---|
| OS rate | 15.2 (2.8) | 18.3 (3.0) | 14.4 (2.7) | 7.6 (2.9) |
| EFS rate | 10.5 (2.3) | 9.2 (2.2) | 9.0 (2.2) | 9.3 (2.2) |
| DFS rate* | 21.5 (4.4) | 17.6 (4.0) | 18.6 (4.2) | 14.5 (3.3) |
| Relapse incidence* | 63.6 (5.2) | 73.9 (4.7) | 72.2 (4.9) | 72.6 (4.2) |
| Death in CR incidence* | 14.9 (3.9) | 8.6 (2.9) | 9.3 (3.2) | 12.9 (3.1) |
| Survival from CR rate* | 26.6 (4.8) | 30.4 (4.9) | 25.1 (4.7) | 24.8 (4.0) |
End point . | Group A, G-CSF-/- . | Group B, G-CSF+/- . | Group C, G-CSF-/+ . | Group D, G-CSF+/+ . |
|---|---|---|---|---|
| OS rate | 15.2 (2.8) | 18.3 (3.0) | 14.4 (2.7) | 7.6 (2.9) |
| EFS rate | 10.5 (2.3) | 9.2 (2.2) | 9.0 (2.2) | 9.3 (2.2) |
| DFS rate* | 21.5 (4.4) | 17.6 (4.0) | 18.6 (4.2) | 14.5 (3.3) |
| Relapse incidence* | 63.6 (5.2) | 73.9 (4.7) | 72.2 (4.9) | 72.6 (4.2) |
| Death in CR incidence* | 14.9 (3.9) | 8.6 (2.9) | 9.3 (3.2) | 12.9 (3.1) |
| Survival from CR rate* | 26.6 (4.8) | 30.4 (4.9) | 25.1 (4.7) | 24.8 (4.0) |
Numbers in parentheses are the standard errors.
Only patients who achieved a complete remission were considered (the number of patients in each group is given in Table 2).